Background
Methods
Mice
Viral vector production
In vitro characterization of Ad-HIVB
VLP purification and Western Blot
Cell surface expression analysis
Immunizations
Experiment | Group | Time | Intervention | Virus | IFU/mouse | Injection site |
---|---|---|---|---|---|---|
Immunogenicity of Ad-HIVB | – | Day 0 | Immunization | Ad-HIVB | 1 × 108 | Lower right leg |
Day 18 | ICS | |||||
Immunogenicity of Ad-Ii-SIVCErvv | – | Day 0 | Immunization | Ad-Ii-SIVCErvv | 2 × 108 | Lower right leg |
Day 14 | ICS | |||||
Heterologous HIV-prime SIV-boost | without Ad-Ii-SIVCErvv | Day 0 | Prime immunization | Ad-HIVB | 1 × 108 | Lower right leg |
Day 50–57 | Bleeding | |||||
Day 63–74 | Boost immunization | MVA-SIV | 5 × 107 | Lower right leg | ||
10 days post boost | Bleeding & ICS | |||||
with Ad-Ii-SIVCErvv | Day 0 | Prime immunization | Ad-HIVB | 1 × 108 | Lower right leg | |
Ad-Ii-SIVCErvv | 1 × 108 | Lower left leg | ||||
Day 50–57 | Bleeding | |||||
Day 63–74 | Boost immunization | MVA-SIV | 5 × 107 | Lower right leg | ||
10 days post boost | Bleeding & ICS | |||||
Homologous SIV-prime SIV-boost | without Ad-Ii-SIVCErvv | Day 0 | Prime immunization | Ad-SIV | 2 × 108 | Upper right leg |
Day 56 | Bleeding & | |||||
Boost immunization | MVA-SIV | 1 × 107 | Upper left leg | |||
Day 311 | Bleeding & ICS | |||||
with Ad-Ii-SIVCErvv | Day 0 | Prime immunization | Ad-SIV | 2 × 108 | Upper right leg | |
Ad-Ii-SIVCErvv | 2 × 108 | Upper left leg | ||||
Day 56 | Bleeding & | |||||
Boost immunization | MVA-SIV | 1 × 107 | Upper left leg | |||
Day 311 | Bleeding & ICS |
Intracellular cytokine staining (ICS)
Antibody response measurements
Statistical analysis
Results
Vaccine design and characterization
Design of VLVs
Ad-HIVB expresses the encoded antigens and is immunogenic in mice
Ad-Ii-SIVCErvv induces T-cell responses to the accessory antigens
Heterologous HIV-prime SIV-boost regimen
CD8+ T-cell responses induced by heterologous HIV-prime SIV-boost regimen
CD4+ T-cell responses induced by the heterologous HIV-prime SIV-boost regimen
Heterologous HIV-prime SIV-boost regimen induced broad Env-specific antibody responses
Correlations of immune responses induced by heterologous HIV-prime SIV-boost regimen
a
Ad-HIVB +MVA-SIV | CD4+ T-cells | CD8+ T-cells | Antibodies | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HIV conB Gag | SIV mac Gag | SIV CE | SIV agm Gag | HIV conB Env | SIV mac Env | HIV conB Gag | SIV mac Gag | SIV CE | SIV agm Gag | HIV conB Env | SIV mac Env | anti-HIV B Env | anti-SIV mac Env | anti-HIV C Env | |
CD4+ T-cells
| |||||||||||||||
HIVconB Gag | |||||||||||||||
SIVmac Gag | 0.479 | ||||||||||||||
SIV CE | 0.333 | 0.292 | |||||||||||||
SIVagm Gag | 0.022 | 0.533 | 0.689 | ||||||||||||
HIVconB Env | 0.019 | 0.673 | 0.275 | 0.044 | |||||||||||
SIVmac Env | 0.096 | 0.977 | 0.400 | 0.044 | 0.098 | ||||||||||
CD8+ T-cells
| |||||||||||||||
HIVconB Gag | 0.233 | 0.453 | 0.306 | 0.800 | 0.648 | 0.513 | |||||||||
SIVmac Gag | 0.043 | 0.984 | 0.785 | 0.400 | 0.211 | 0.072 | 0.023 | ||||||||
SIV CE | 0.600 | 0.900 | 0.100 | 1.000 | 0.200 | 0.800 | 0.600 | 0.800 | |||||||
SIVagm Gag | |||||||||||||||
HIVconB Env | 0.007 | 1.000 | 0.253 | 0.044 | 0.012 | 0.017 | 0.072 |
0.002
| 0.200 | ||||||
SIVmac Env | 0.931 | 0.333 | 0.067 | 0.611 | 1.000 | 1.000 | 0.214 | 0.500 | 0.200 | 0.722 | |||||
Antibodies
| |||||||||||||||
anti-HIV B Env | 0.330 | 0.274 | 0.025 | 0.956 | 0.442 | 0.427 | 0.013 | 0.159 | 0.200 | 0.187 | 0.008 | ||||
anti-SIVmac Env | 0.973 | 0.794 | 0.531 | 0.867 | 0.556 | 0.233 | 0.407 | 0.246 | 0.600 | 0.335 | 0.039 | 0.096 | |||
anti-HIV C Env | 0.707 | 0.962 | 0.264 | 0.911 | 0.383 | 0.387 | 0.096 | 0.199 | 0.400 | 0.230 | 0.031 | 0.015 |
0.001
|
b
Ad-HIVB + Ad-Ii-SIVCErvv +MVA-SIV | CD4+ T-cells | CD8+ T-cells | Antibodies | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HIV conB Gag | SIV mac Gag | SIV CE | SIV agm Gag | HIV conB Env | SIV mac Env | HIV conB Gag | SIV mac Gag | SIV CE | SIV agm Gag | HIV conB Env | SIV mac Env | anti-HIV B Env | anti-SIV mac Env | anti-HIV C Env | |
CD4+ T-cells
| |||||||||||||||
HIVconB Gag | |||||||||||||||
SIVmac Gag | 0.110 | ||||||||||||||
SIV CE | 0.300 | 0.006 | |||||||||||||
SIVagm Gag | 0.064 |
2.6E−04
| 0.010 | ||||||||||||
HIVconB Env | 0.645 | 0.010 | 0.024 | 0.042 | |||||||||||
SIVmac Env | 0.042 | 0.599 | 0.475 | 0.639 | 1.000 | ||||||||||
CD8+ T-cells
| |||||||||||||||
HIVconB Gag |
5.5E−07
| 0.110 | 0.300 | 0.064 | 0.645 | 0.042 | |||||||||
SIVmac Gag | 0.110 |
6.6E−06
| 0.006 |
2.6E−04
| 0.010 | 0.599 | 0.110 | ||||||||
SIV CE | 0.300 | 0.006 |
6.6E−06
| 0.010 | 0.024 | 0.475 | 0.300 | 0.006 | |||||||
SIVagm Gag | 0.064 |
2.6E−04
| 0.010 |
3.3E−05
| 0.042 | 0.639 | 0.064 |
2.6E−04
| 0.010 | ||||||
HIVconB Env | 0.645 | 0.010 | 0.024 | 0.042 |
5.5E−07
| 1.000 | 0.645 | 0.010 | 0.024 | 0.042 | |||||
SIVmac Env | 0.042 | 0.599 | 0.475 | 0.639 | 1.000 |
0.001
| 0.042 | 0.599 | 0.475 | 0.639 | 1.000 | ||||
Antibodies
| |||||||||||||||
anti-HIV B Env | 0.075 | 0.299 | 0.122 | 0.215 | 0.462 | 0.008 | 0.075 | 0.299 | 0.122 | 0.215 | 0.462 | 0.008 | |||
anti-SIVmac Env | 0.168 | 0.205 | 0.552 | 0.316 | 0.162 | 0.156 | 0.168 | 0.205 | 0.552 | 0.316 | 0.162 | 0.156 | 0.096 | ||
anti-HIV C Env | 0.125 | 0.528 | 0.375 | 0.394 | 0.399 | 0.039 | 0.125 | 0.528 | 0.375 | 0.394 | 0.399 | 0.039 |
0.002
| 0.031 |
Homologous SIV-prime SIV-boost regimen
CD8+ T-cell responses induced by homologous SIV-prime SIV-boost regimen
CD4+ T-cell responses induced by homologous SIV-prime SIV-boost regimen
Antibody responses induced by homologous SIV-prime SIV-boost regimen
Correlation of immune responses induced by homologous SIV-prime SIV-boost regimen
a
Ad-SIV + MVA-SIV | CD4+ T-cells | CD8+ T-cells | Antibodies | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gag | Env | Rev | Vif | Vpr | Gag | Env | Rev | Vif | Vpr | AUC | Titer | Avidity | |
CD4+ T-cells
| |||||||||||||
Gag | |||||||||||||
Env | 0.086 | ||||||||||||
Rev | 0.085 | 0.834 | |||||||||||
Vif | 0.694 | 0.250 | 0.792 | ||||||||||
Vpr | 0.262 | 0.731 | 0.342 | 0.444 | |||||||||
CD8+ T-cells
| |||||||||||||
Gag | 0.678 | 1.018 | 0.151 | 0.500 | 0.363 | ||||||||
Env | 0.437 | 0.410 | 0.611 | 0.889 | 0.082 | 0.017 | |||||||
Rev | 0.516 | 0.131 | 0.960 | 0.583 | 0.187 | 0.226 | 0.226 | ||||||
Vif | 0.476 | 0.901 | 0.181 | 1.000 | 0.782 | 0.615 | 0.460 | 0.940 | |||||
Vpr | 0.667 | 1.111 | 0.889 | 0.222 | 0.889 | 0.667 | 0.444 | 1.000 | 0.333 | ||||
Antibodies
| |||||||||||||
AUC | 0.097 | 0.776 | 0.228 | 0.944 | 0.853 | 0.644 | 0.948 | 0.583 | 0.226 | 0.444 | |||
Titer | 0.263 | 0.630 | 0.337 | 0.889 | 0.673 | 0.616 | 0.913 | 0.230 | 0.480 | 0.667 |
0.001
| ||
Avidity | 0.083 | 1.000 | 0.139 | 1.583 | 0.056 | 0.583 | 0.778 | 1.417 | 1.417 | 1.778 | 1.000 | 0.750 |
b
Ad-SIV + Ad-Ii-SIVCErvv + MVA-SIV | CD4+ T-cells | CD8+ T-cells | Antibodies | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gag | Env | Rev | Vif | Vpr | Gag | Env | Rev | Vif | Vpr | AUC | Titer | Avidity | |
CD4+ T-cells
| |||||||||||||
Gag | |||||||||||||
Env | 0.046 | ||||||||||||
Rev | 0.629 | 0.015 | |||||||||||
Vif | 0.182 | 0.223 | 0.079 | ||||||||||
Vpr | 0.014 |
0.002
| 0.074 | 0.111 | |||||||||
CD8+ T-cells
| |||||||||||||
Gag | 0.461 | 0.496 | 0.463 | 0.459 | 0.862 | ||||||||
Env | 0.296 | 0.106 | 0.256 | 0.866 | 0.305 | 0.081 | |||||||
Rev | 0.503 | 0.777 | 0.430 | 0.150 | 0.307 | 0.125 | 0.828 | ||||||
Vif | 0.665 | 0.909 | 0.748 | 0.955 | 0.456 | 0.911 | 0.306 | 0.763 | |||||
Vpr | 0.116 | 0.480 | 0.896 | 1.002 | 0.082 | 0.220 | 0.845 | 0.144 | 0.199 | ||||
Antibodies
| |||||||||||||
AUC | 0.075 | 0.164 | 0.515 | 0.477 | 0.221 | 0.843 | 0.230 | 0.422 | 0.389 | 0.853 | |||
Titer | 0.040 | 0.157 | 0.558 | 0.272 | 0.085 | 0.738 | 0.629 | 0.725 | 0.410 | 0.512 | 0.004 | ||
Avidity | 0.053 | 0.112 | 0.458 | 0.346 | 0.127 | 0.804 | 0.601 | 0.495 | 0.798 | 0.798 |
0.002
|
0.002
|